As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...
Clinical Trials Arena on MSN4d
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...
WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...
Wave Life Sciences Ltd. plans to file with the U.S. FDA for accelerated approval of WVE-N531, an exon skipping ...
Clinical Trials Arena on MSN13d
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patientsThe company plans to submit a biologics licence application to the US Food and Drug Administration later this year.
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
The exon-skipping drug was approved by the FDA for DMD patients with mutations in the dystrophin gene amenable to exon 53 skipping, a group that accounts for around 8% of the total DMD population.
The trial has enrolled a number of boys and young men with DMD who are amenable to exon-51 skipping. CONNECT2 is a 25-week, multinational, double-blind, placebo-controlled trial with multiple ...
Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular Dystrophy (DMD), WVE-N531, has met all trial endpoints, showing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback